Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain

Award Number: R44NS081887
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/15/2012
PERIOD OF PERFORMANCE END DATE: 03/31/2019

Group Awards By:

View Award Description

Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain - PROJECT SUMMARY This program aims to develop a novel, non-opioid therapeutic for the treatment of pain that targets a subtype of the human voltage-gated Na+ ion channel, NaV1.7. Preliminary data indicate that SiteOne's lead drug candidates may be more effective than opioids for treating certain types of pain, and lack the side effects associated with opioid analgesics, which include nausea, drowsiness, respiratory depression and potential for addiction. Voltage-gated Na+ ion channels are integral membrane proteins responsible for the transmission of signals along electrically conducting cells. Ten mammalian genes have been sequenced, which encode ten distinct channel isoforms (NaV1.1-1.9 and NaX), each having unique gating properties, and cellular and tissue distribution patterns. Recent studies have correlated a hereditary loss-of-function mutation in one human Na+ channel isoform – NaV1.7 – with a rare genetic disorder known as Congenital Insensitivity to Pain (CIP). Individuals with CIP have reduced sensitivity to normally painful stimuli without significant deficits to sensory or cognitive function. A compelling body of evidence indicates that selective inhibition of NaV1.7 in normal humans could recapitulate the phenotype of CIP. However, the high homology of human NaV proteins, coupled with challenges associated with high-throughput screening against multiple ion channel targets, have thwarted most efforts to develop selective antagonists for individual NaV subtypes. SiteOne has identified a small collection of drug candidates that exhibit 100 to 2000-fold selectivity for inhibition of human NaV1.7 over other peripheral human NaV isoforms. During Phase I and Phase II of our program, lead drug candidates were discovered by leveraging a two amino acid variation in the pore region of NaV1.7 that is not present in any other human NaV isoform. These compounds have been advanced through a series of in vitro and in vivo pharmacology, pharmacokinetic, safety and efficacy studies. During Phase IIB of our program, we aim to improve the synthetic route to a single lead drug candidate, manufacture multi-hundred gram quantities of this compound, and complete characterization, pharmacology and safety studies in support of an Investigational New Drug application. Success of this program will lead to the filing of an IND and support advancement of a novel, selective inhibitor of NaV1.7 into clinical testing.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2017	SITEONE THERAPEUTICS, INC.	203 ENTERPRISE BLVD STE 3	BOZEMAN	MT	59718	GALLATIN	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	3/11/2019	NON-COMPETING CONTINUATION	$0
2019	2017	SITEONE THERAPEUTICS, INC.	351 EVERGREEN DR STE B-1	BOZEMAN	MT	59715	GALLATIN	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	8/13/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $829,314 )
2017	2017	SITEONE THERAPEUTICS, INC.	203 ENTERPRISE BLVD STE 3	BOZEMAN	MT	59718	GALLATIN	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	8/18/2017	NON-COMPETING CONTINUATION	$829,314
2017	2015	SITEONE THERAPEUTICS, INC.	203 ENTERPRISE BLVD STE 3	BOZEMAN	MT	59718	GALLATIN	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	8/16/2017	NON-COMPETING CONTINUATION	$0
														Subtotal = $829,314

Issue Date FY: 2016 ( Subtotal = $616,855 )
2016	2016	SITEONE THERAPEUTICS INC	600 CASTLE HILL ROAD	REDWOOD CITY	CA	94061	SAN MATEO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	7/19/2016	COMPETING CONTINUATION	$616,855
														Subtotal = $616,855

Issue Date FY: 2015 ( Subtotal = $756,321 )
2015	2015	SITEONE THERAPEUTICS INC	600 CASTLE HILL ROAD	REDWOOD CITY	CA	94061	SAN MATEO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	9/10/2015	NON-COMPETING CONTINUATION	$756,321
														Subtotal = $756,321

Issue Date FY: 2014 ( Subtotal = $681,135 )
2014	2014	SITEONE THERAPEUTICS INC	600 CASTLE HILL ROAD	REDWOOD CITY	CA	94061	SAN MATEO	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	9/11/2014	COMPETING CONTINUATION	$681,135
														Subtotal = $681,135

Grand Total All Awards = $2,883,625

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Selective Inhibitors of NaV1.7 as Therapeutics for Pain

Award Number: R44NS081887

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/15/2012

PERIOD OF PERFORMANCE END DATE: 03/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer